Skip to main content
SpringerLink
Log in

Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R (2005) FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10(3):176–182

    Article  PubMed  CAS  Google Scholar 

  2. Buckstein R, Yee K, Wells RA (2011) 5-azacytidine in myelodysplastic syndromes: a clinical practice guideline. Cancer Treat Rev 37(2):160–167

    Article  PubMed  CAS  Google Scholar 

  3. San Miguel Amigo L, Franco Osorio R, Mercadal Vilchez S, Martinez-Frances A (2011) Azacitidine adverse effects in patients with myelodysplastic syndromes. Adv Ther 28(Suppl 4):6–11

    Article  PubMed  CAS  Google Scholar 

  4. Santini V, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Silverman LR, List A, Gore SD, Seymour JF, Backstrom J, Beach CL (2010) Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol 85(2):130–138

    PubMed  CAS  Google Scholar 

  5. Platzbecker U, Aul C, Ehninger G, Giagounidis A (2010) Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Ann Hematol 89(4):427–428

    Article  PubMed  Google Scholar 

  6. Issa JP, Kantarjian HM, Kirkpatrick P (2005) Azacitidine. Nat Rev Drug Discov 4(4):275–276

    Article  PubMed  CAS  Google Scholar 

  7. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer 11(10):726–734

    Article  PubMed  CAS  Google Scholar 

  8. Tsai HC, Baylin SB (2011) Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 21(3):502–517

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

G.F. was supported by the German Cancer Foundation (Deutsche Krebshilfe) grants number 109215 and 109929 as well as by the European Community’s Seventh Framework Program (FP7-2007–2013) under grant agreement HEALTH-F2-2011-256986.

Conflict of interest

M. v. L-T. received honoraria and travel grants from Celgene (Munich, Germany). The other authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Internal Medicine 3, Center of Integrated Oncology (CIO) Cologne-Bonn, University Hospital of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany

    Georg Feldmann, Peter Brossart & Marie von Lilienfeld-Toal

  2. Hematology/Oncology, Jena University Hospital, Jena, Germany

    Marie von Lilienfeld-Toal

Authors
  1. Georg Feldmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Brossart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marie von Lilienfeld-Toal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georg Feldmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feldmann, G., Brossart, P. & von Lilienfeld-Toal, M. Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment. Ann Hematol 92, 1577–1579 (2013). https://doi.org/10.1007/s00277-013-1748-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1748-7

Keywords

Search

Navigation